Chan Wing-Lok, Cheng Matthew Ho-Fai, Wu Jacky Tsun-Kit, Choi Cheuk-Wai, Tse Rosa Piu-Ying, Ho Patty Piu-Ying, Cheung Emina Edith, Cheung Andy, Test Ka-Yu, Chan Karen Kar-Loen, Ngan Hexane Yuen-Sheung, Siu Steven Wai-Kwan, Ngan Roger Kai-Cheong, Lee Anne Wing-Mui
Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Cancers (Basel). 2022 Aug 15;14(16):3934. doi: 10.3390/cancers14163934.
(1) Background: To report the long-term clinical outcomes of computer-tomography (CT)-guided brachytherapy (BT) for locally advanced cervical cancer. (2) Methods: A total of 135 patients with FIGO stage IB-IVA cervical cancer treated with definitive radiotherapy +/- chemotherapy with an IGABT boost at Queen Mary Hospital, Hong Kong, between November 2013 and December 2019 were included. Treatment included pelvic radiotherapy 40 Gy/20 Fr/4 weeks +/- chemotherapy then CT-guided BT (7 Gy × 4 Fr) and a sequential parametrial boost. The primary outcome was local control. Secondary outcomes were pelvic control, distant metastasis-free survival, overall survival (OS) and late toxicities. (3) Results: The median follow-up was 53.6 months (3.0-99.6 months). The five-year local control, pelvic control, distant metastasis-free survival and OS rates were 90.7%, 84.3%, 80.0% and 87.2%, respectively. The incidence of G3/4 long-term toxicities was 6.7%, including proctitis (2.2%), radiation cystitis (1.5%), bowel perforation (0.7%), ureteric stricture (0.7%) and vaginal stenosis and fistula (0.7%). Patients with adenocarcinomas had worse local control (HR 5.82, 95% CI 1.84-18.34, = 0.003), pelvic control (HR 4.41, 95% CI 1.83-10.60, = 0.001), distant metastasis-free survival (HR 2.83, 95% CI 1.17-6.84, = 0.021) and OS (HR 4.38, 95% CI: 1.52-12.67, = 0.003) rates. Distant metastasis-free survival was associated with HR-CTV volume ≥ 30 cm (HR 3.44, 95% CI 1.18-9.42, = 0.025) and the presence of pelvic lymph node (HR 3.44, 95% CI 1.18-9.42, = 0.025). OS was better in patients with concurrent chemotherapy (HR 4.33, 95% CI: 1.40-13.33, = 0.011). (4) Conclusions: CT-guided BT for cervical cancer achieved excellent long-term local control and OS. Adenocarcinoma was associated with worse clinical outcomes. (4) Conclusion: CT-guided BT for cervical cancer achieved excellent long-term local control and OS. Adenocarcinoma was associated with worse clinical outcomes.
(1)背景:报告计算机断层扫描(CT)引导下近距离放射治疗(BT)用于局部晚期宫颈癌的长期临床结果。(2)方法:纳入2013年11月至2019年12月在香港玛丽医院接受根治性放疗±化疗并联合影像引导自适应近距离放疗(IGABT)增敏治疗的135例国际妇产科联盟(FIGO)分期为IB-IVA期的宫颈癌患者。治疗包括盆腔放疗40 Gy/20次/4周±化疗,然后进行CT引导下BT(7 Gy×4次)及序贯宫旁组织增敏放疗。主要结局为局部控制。次要结局为盆腔控制、无远处转移生存期、总生存期(OS)及晚期毒性反应。(3)结果:中位随访时间为53.6个月(3.0 - 99.6个月)。5年局部控制率、盆腔控制率、无远处转移生存率及OS率分别为90.7%、84.3%、80.0%和87.2%。3/4级长期毒性反应发生率为6.7%,包括直肠炎(2.2%)、放射性膀胱炎(1.5%)、肠穿孔(0.7%)、输尿管狭窄(0.7%)以及阴道狭窄和瘘(